MHSC
Senior Moderator
1 in 10 health-care workers treating Ebola get infected
NEW YORK ? One in 10 health-care workers treating Ebola patients in West Africa are becoming infected with the disease, the World Health Organization announced in Geneva Friday in an international media teleconference at the conclusion of an emergency meeting on the outbreak.
...
The organization said the rush to introduce experimental drugs was ?unprecedented? due to the severity of the West Africa outbreak and the need to short-circuit normal government regulatory processes that typically take years.
...
One of the new treatments is the chimpanzee adenovirus serotype 3 (ChAd3) vaccine, which uses a chimpanzee adenovirus containing the gene for the Ebola virus surface protein. The other is recombinant vesicular stomatitis virus (rVSV) vaccine, which aims to induce Ebola-specific immune responses.
A background paper prepared by the WHO for the conference indicated there is no information available on the preliminary human trials of an early form of the ChAd3 vaccine, which contains two Ebola strains, Zaire and Sudan. Human trials are scheduled to start in the U.S. and the U.K. almost immediately.
http://www.wnd.com/2014/09/who-1-in-10-treating-ebola-become-infected/
NEW YORK ? One in 10 health-care workers treating Ebola patients in West Africa are becoming infected with the disease, the World Health Organization announced in Geneva Friday in an international media teleconference at the conclusion of an emergency meeting on the outbreak.
...
The organization said the rush to introduce experimental drugs was ?unprecedented? due to the severity of the West Africa outbreak and the need to short-circuit normal government regulatory processes that typically take years.
...
One of the new treatments is the chimpanzee adenovirus serotype 3 (ChAd3) vaccine, which uses a chimpanzee adenovirus containing the gene for the Ebola virus surface protein. The other is recombinant vesicular stomatitis virus (rVSV) vaccine, which aims to induce Ebola-specific immune responses.
A background paper prepared by the WHO for the conference indicated there is no information available on the preliminary human trials of an early form of the ChAd3 vaccine, which contains two Ebola strains, Zaire and Sudan. Human trials are scheduled to start in the U.S. and the U.K. almost immediately.
http://www.wnd.com/2014/09/who-1-in-10-treating-ebola-become-infected/